This analysis found that SGLT2 inhibitors reduced the risk of kidney disease progression by 40% (relative risk 0.60, 95% CI 0.46–0.78) in patients with glomerular diseases, which was similar between disease subcategories of IgAN, focal segmental glomerulosclerosis (FSGS) and other glomerulopathies. Here, SLC5A2 is linked to glomerular disorder.